Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients

World Journal of Gastroenterology

Volumn 12, Issue 9, 2006, Pages 1412-1415

  Kobayashi, Michiya ^a   Sakamoto, Junichi ^b   Namikawa, Tsutomu ^a   Okamoto, Ken ^a   Okabayashi, Takehiro ^a   Ichikawa, Kengo ^a   Araki, Keijiro ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Gastric cancer; Paclitaxel; Peritoneal carcinomatosis; Pharmacokinetic study

Indexed keywords

CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; FLUOROURACIL; PACLITAXEL; RANITIDINE;

ADVANCED CANCER; ARTICLE; ASCITES FLUID; ASCITES FLUID LEVEL; BONE MARROW SUPPRESSION; CARCINOMATOUS PERITONITIS; CASE REPORT; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG INFUSION; HUMAN; STOMACH CANCER;

EID: 33645520134     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i9.1412     Document Type: Article

References (25)

1. Rowinsky EK, Donehower RC. Paclitaxel (taxol) N Engl J Med 1995; 332: 1004-1014
2. Chang YF, Li LL, Wu CW, Liu TY, Lui WY, P'eng FK, Chi CW. Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 1996; 77: 14-18
3. Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, Kim CS, Rhyu HS, Hyun JH, Kim JS. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 1999; 85: 295-301
4. Murad AM, Petroianu A, Guimaraes RC, Aragao BC, Cabral LO, Scalabrini-Neto AO. Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. Am J Clin Oncol 1999; 22: 580-586
5. Lokich JJ, Sonneborn H, Anderson NR, Bern MM, Coco FV, Dow E, Oliynyk P. Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas. Cancer 1999; 85: 2347-2351
6. Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempel V, Clemens M, Kanz L, Bokemeyer C. A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2000; 83: 458-462
7. Garcia AA, Leichman CG, Lenz HJ, Baranda J, Lujan R, Casagrande Y, Leichman L. Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomach. Jpn J Clin Oncol 2001; 31: 275-278
8. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, Miyata Y, Taguchi T. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 2001; 12: 1133-1137
9. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987; 5: 1232-1239
10. Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG. Direct diffusion of cis-diamminedichloroplatinum (II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 1989; 49: 3380-3384
11. Los G, Mutsaers PH, Lenglet WJ, Baldew GS, McVie JG. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 1990; 25: 389-394
12. Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. J Clin Oncol 1995; 13: 2961-2967
13. Markman M. Intraperitoneal taxol. Cancer Treat Res 1996; 81: 1-5
14. Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol 1998; 16: 2620-2624
15. O'Boyle KP, Wang Y, Schwartz EL, Regl DL, Einzig A, Dutcher JP, Wiernik PH, Horwitz SB. Development of two radioimmunoassays to detect paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids. Cancer 1997; 79: 1022-1030
16. Ishida T, Shimokawa H, Kawaguchi K, Nose N, Ikegami T, Itoh H, Kido A, Sasaki Y, Ezaki T. Effective weekly paclitaxel administration for gastric cancer with malignant ascites--a case report. Gan To Kagaku Ryoho 2002; 29: 1643-1646
17. Cho H, Kanari M, Sano H, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Imada T. A case of metastatic gastric cancer responding to weekly administration of paclitaxel as a second-line therapy Gan To Kagaku Ryoho 2003; 30: 129-132
18. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, Bonadonna G, Egorin MJ. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13: 180-190
19. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987; 47: 2486-2493
20. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 1988; 48: 4093-4100
21. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990; 82: 1247-1259
22. Markman M. Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity. Cancer Treat Rev 1986; 13: 219-242
23. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr, Rubin S, Curtin J, Barakat R, Phillips M. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol 1992; 10: 1485-1491
24. Rowinsky EK, Burke PJ, Karp JE, Tucker RW, Ettinger DS, Donehower RC. Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res 1989; 49: 4640-4647
25. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980; 77: 1561-1565